<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157350</url>
  </required_header>
  <id_info>
    <org_study_id>OUH-4202-ID-2018</org_study_id>
    <secondary_id>S-20140046</secondary_id>
    <nct_id>NCT02157350</nct_id>
  </id_info>
  <brief_title>The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT</brief_title>
  <acronym>IMPETUS-D</acronym>
  <official_title>A Prospective Study to Identify Predictive Factors for Progression and Regression of Proliferative Diabetic Retinopathy in Patients Receiving Standard Panretinal Laser Photocoagulation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yamagata University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the threshold level of proliferative diabetic
      retinopathy progression and regression after standard panretinal photocoagulation. Predictors
      of progression and regression will be identified which will include retinal vessel geometry
      (caliber, fractals and tortuosity), retinal vessel oxygen saturation and retinal areas of
      non-perfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMPETUS 2018 - DETECT is a six-month prospective study involving 90 treatment-naïve diabetes
      patients with proliferative diabetic retinopathy (PDR) referred for panretinal laser
      photocoagulation (PRP) treatment to the Department of Ophthalmology, Odense University
      Hospital between July 1st 2014 and June 30th 2015.

      Project information will be given prior to the study to the ophthalmological departments of
      and to all private practicing ophthalmologists in the Region of Southern Denmark. Patients
      will at baseline have a standard examination that will include wide-field fundus photography,
      wide-field fluorescein angiography and spectral domain optical coherence tomography (SD-OCT)
      in order to confirm the diagnosis of PDR. If they meet the criteria of inclusion and not
      those of exclusion, they will be informed of the study verbally and writing and offered the
      chance to participate. Prior to the first session of PRP patients enrolled in the study will
      receive the rest of the baseline examinations including retinal oximetry. Standard PRP
      treatment will be given in two sessions by a trained doctor.

      Patients will be re-examined at month 3 and 6 and progression/regression of PDR will be
      evaluated by measuring the amount of fluorescein leakage by wide-field fluorescein
      angiography at 1, 5 and 10 minutes. For patients with regression, supplementary PRP will be
      offered. After the final examination at month 6, patients will be referred back to their
      primary ophthalmologist.

      A study nurse and a photographer will be assigned to the project. All examinations will be
      standardized and the study crew will be fully certified. Data will be analyzed with respect
      to the endpoint of the study (Stata 13, StataCorp, College Station, Texas) and also used to
      create the algorithm to be used for individualized treatment in IMPETUS 2018 - TREAT.

      In the Region of Southern Denmark it is estimated that 200 treatment naïve patients with PDR
      will be referred for treatment annually. With an estimated participation rate of 50% and a
      subsequent dropout rate of 10%, IMPETUS 2018 - DETECT will include 90 patients. A traditional
      power calculation is not feasibly due to the design of the study with multiple outcomes
      studies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proliferative diabetic retinopathy progression/regression.</measure>
    <time_frame>Change from baseline in proliferative diabetic retinopathy at 6 months</time_frame>
    <description>Progression/regression of proliferative diabetic retinopathy will be evaluated by measuring the amount of fluorescein leakage by wide-field fluorescein angiography at 1, 5 and 10 minutes. These measurements will be performed at baseline, and during followup after panretinal photocoagulation (3 months and 6 months).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal vessel geometry (caliber, fractals and tortuosity)</measure>
    <time_frame>Measurements assessed at baseline and 3 and 6 months after panretinal laser photocoagulation.</time_frame>
    <description>Change in vessel geometry:
Caliber: Using a computerised program - SIVA / IVAN. Fractals: Using a computerised program - SIVA. Tortuosity: Using a computerised program - SIVA</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Retinal vessel oxygen saturation</measure>
    <time_frame>Measurements assessed at baseline and 3 and 6 months after panretinal laser photocoagulation.</time_frame>
    <description>Oxymap T1 with the Oxymap Analyser. Non-invasively measuring the vessel saturation of both arterioles and venules in percentage.</description>
  </other_outcome>
  <other_outcome>
    <measure>Retinal areas of non-perfusion.</measure>
    <time_frame>Measurements assessed at baseline and 3 and 6 months after panretinal laser photocoagulation.</time_frame>
    <description>Using wide-field fluorescein angiography</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Panretinal Laser Photocoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See interventional description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Panretinal laser photocoagulation</intervention_name>
    <description>Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.</description>
    <arm_group_label>Panretinal Laser Photocoagulation</arm_group_label>
    <other_name>NAVILAS laser</other_name>
    <other_name>Retinal Laser Photocoagulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus

          -  Proliferative diabetic retinopathy of one or both eyes

        Exclusion Criteria:

          -  Diabetic macular edema on current eye

          -  Earlier PRP treatment on current eye

          -  Cataract demanding treatment on current eye

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L Torp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Unit of Ophthalmology, University of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joakob Grauslund, DMSci, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Research Unit of Ophthalmology, University of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tundo Peto, PhD,FHCO</last_name>
    <role>Study Chair</role>
    <affiliation>NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tien Y Wong, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Ophthalmology National University of Singapore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ryo Kawasaki, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Public Health Ophthalmology, Yamagata</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Unit of Ophthalmology, Clinical Institute, University of Southern Denmark, Department of Ophthalmology, Odense University Hospital.</name>
      <address>
        <city>Odense</city>
        <state>Fyn</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://komite.regionsyddanmark.dk/wm258128</url>
    <description>The Regional Scientific Ethical Committees for Southern Denmark</description>
  </link>
  <link>
    <url>http://www.datatilsynet.dk/</url>
    <description>The Danish Data Protection Agency</description>
  </link>
  <link>
    <url>http://www.ouh.dk/wm122110</url>
    <description>Odense University Hospital</description>
  </link>
  <link>
    <url>http://www.sdu.dk/en/forskning/phd</url>
    <description>University of Southern denmark</description>
  </link>
  <reference>
    <citation>Grauslund J, Green A, Sjølie AK. Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients. Ophthalmology. 2009 Nov;116(11):2170-4. doi: 10.1016/j.ophtha.2009.04.043. Epub 2009 Sep 10.</citation>
    <PMID>19744716</PMID>
  </reference>
  <reference>
    <citation>Grauslund J, Green A, Sjølie AK. Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia. 2009 Sep;52(9):1829-35. doi: 10.1007/s00125-009-1450-4. Epub 2009 Jul 12.</citation>
    <PMID>19593541</PMID>
  </reference>
  <reference>
    <citation>Stefánsson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol. 2006 Jul-Aug;51(4):364-80. Review.</citation>
    <PMID>16818083</PMID>
  </reference>
  <reference>
    <citation>Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976 Apr;81(4):383-96.</citation>
    <PMID>944535</PMID>
  </reference>
  <reference>
    <citation>Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981 Jul;88(7):583-600.</citation>
    <PMID>7196564</PMID>
  </reference>
  <reference>
    <citation>Ferris FL 3rd, Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12. Ophthalmology. 1987 Jul;94(7):754-60.</citation>
    <PMID>3658347</PMID>
  </reference>
  <reference>
    <citation>Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):766-85.</citation>
    <PMID>2062512</PMID>
  </reference>
  <reference>
    <citation>Klein R, Klein BE, Moss SE, Wong TY, Hubbard L, Cruickshanks KJ, Palta M. The relation of retinal vessel caliber to the incidence and progression of diabetic retinopathy: XIX: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2004 Jan;122(1):76-83.</citation>
    <PMID>14718299</PMID>
  </reference>
  <reference>
    <citation>Rogers SL, Tikellis G, Cheung N, Tapp R, Shaw J, Zimmet PZ, Mitchell P, Wang JJ, Wong TY. Retinal arteriolar caliber predicts incident retinopathy: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care. 2008 Apr;31(4):761-3. doi: 10.2337/dc07-1622. Epub 2008 Jan 9.</citation>
    <PMID>18184895</PMID>
  </reference>
  <reference>
    <citation>Klein R, Klein BE, Moss SE, Wong TY. Retinal vessel caliber and microvascular and macrovascular disease in type 2 diabetes: XXI: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology. 2007 Oct;114(10):1884-92. Epub 2007 May 30.</citation>
    <PMID>17540447</PMID>
  </reference>
  <reference>
    <citation>Grauslund J, Hodgson L, Kawasaki R, Green A, Sjølie AK, Wong TY. Retinal vessel calibre and micro- and macrovascular complications in type 1 diabetes. Diabetologia. 2009 Oct;52(10):2213-7. doi: 10.1007/s00125-009-1459-8. Epub 2009 Jul 18.</citation>
    <PMID>19618163</PMID>
  </reference>
  <reference>
    <citation>Grauslund J, Green A, Kawasaki R, Hodgson L, Sjølie AK, Wong TY. Retinal vascular fractals and microvascular and macrovascular complications in type 1 diabetes. Ophthalmology. 2010 Jul;117(7):1400-5. doi: 10.1016/j.ophtha.2009.10.047. Epub 2010 Feb 21.</citation>
    <PMID>20176399</PMID>
  </reference>
  <reference>
    <citation>Sasongko MB, Wong TY, Nguyen TT, Cheung CY, Shaw JE, Wang JJ. Retinal vascular tortuosity in persons with diabetes and diabetic retinopathy. Diabetologia. 2011 Sep;54(9):2409-16. doi: 10.1007/s00125-011-2200-y. Epub 2011 May 29.</citation>
    <PMID>21625945</PMID>
  </reference>
  <reference>
    <citation>Jørgensen CM, Hardarson SH, Bek T. The oxygen saturation in retinal vessels from diabetic patients depends on the severity and type of vision-threatening retinopathy. Acta Ophthalmol. 2014 Feb;92(1):34-9. doi: 10.1111/aos.12283. Epub 2013 Dec 16.</citation>
    <PMID>24330421</PMID>
  </reference>
  <reference>
    <citation>Ober MD, Kernt M, Cortes MA, Kozak I. Time required for navigated macular laser photocoagulation treatment with the Navilas. Graefes Arch Clin Exp Ophthalmol. 2013 Apr;251(4):1049-53. doi: 10.1007/s00417-012-2119-0. Epub 2012 Aug 7.</citation>
    <PMID>22868445</PMID>
  </reference>
  <reference>
    <citation>Kernt M, Cheuteu R, Vounotrypidis E, Haritoglou C, Kampik A, Ulbig MW, Neubauer AS. Focal and panretinal photocoagulation with a navigated laser (NAVILAS®). Acta Ophthalmol. 2011 Dec;89(8):e662-4. doi: 10.1111/j.1755-3768.2010.02017.x. Epub 2010 Oct 14.</citation>
    <PMID>20946326</PMID>
  </reference>
  <reference>
    <citation>Hardarson SH. Retinal oximetry. Acta Ophthalmol. 2013 Aug;91(5):489-90. doi: 10.1111/aos.12239.</citation>
    <PMID>23844858</PMID>
  </reference>
  <reference>
    <citation>Geirsdottir A, Palsson O, Hardarson SH, Olafsdottir OB, Kristjansdottir JV, Stefánsson E. Retinal vessel oxygen saturation in healthy individuals. Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5433-42. doi: 10.1167/iovs.12-9912.</citation>
    <PMID>22786895</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Lee Torp</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Eye Diseases</keyword>
  <keyword>Proliferative Diabetic Retinopathy</keyword>
  <keyword>Retinal Vessel Geometry</keyword>
  <keyword>Retinal Oxymetry</keyword>
  <keyword>Retina Ischemia</keyword>
  <keyword>Panretinal Photocoagulation</keyword>
  <keyword>Lasers, Semiconductor</keyword>
  <keyword>Fluorescein Angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

